BBIO BridgeBio Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BBIO

Price (delayed)

$27.05

Market cap

$5.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.22

Enterprise value

$6.32B

BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in ...

Highlights
The gross profit has soared by 188% YoY
BridgeBio Pharma's revenue has soared by 181% YoY
BridgeBio Pharma's quick ratio has soared by 70% from the previous quarter but it has decreased by 2.2% YoY
BBIO's net income is down by 27% year-on-year but it is up by 16% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://bridgebio.com
Peers: OPK OPTN

Key stats

What are the main financial stats of BBIO
Market
Shares outstanding
187.13M
Market cap
$5.06B
Enterprise value
$6.32B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
22.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.89
Earnings
Revenue
$218.6M
EBIT
-$453.62M
EBITDA
-$443.1M
Free cash flow
-$604.92M
Per share
EPS
-$3.22
Free cash flow per share
-$3.39
Book value per share
-$5.97
Revenue per share
$1.22
TBVPS
$4.61
Balance sheet
Total assets
$849.33M
Total liabilities
$1.89B
Debt
$1.73B
Equity
-$1.05B
Working capital
$641.95M
Liquidity
Debt to equity
-1.65
Current ratio
5.54
Quick ratio
5.34
Net debt/EBITDA
-2.83
Margins
EBITDA margin
-202.7%
Gross margin
98.9%
Net margin
-246.2%
Operating margin
-215.6%
Efficiency
Return on assets
-84.3%
Return on equity
N/A
Return on invested capital
-25.3%
Return on capital employed
-64.1%
Return on sales
-207.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
1.31%
1 week
3.28%
1 month
14.81%
1 year
-16.54%
YTD
-32.99%
QTD
6.79%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$218.6M
Gross profit
$216.2M
Operating income
-$471.38M
Net income
-$538.26M
Gross margin
98.9%
Net margin
-246.2%
The gross profit has soared by 188% YoY
BridgeBio Pharma's revenue has soared by 181% YoY
BBIO's operating margin has soared by 97% QoQ and by 64% YoY
BBIO's net margin has surged by 96% since the previous quarter and by 55% year-on-year

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
22.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.89
BBIO's EPS is up by 18% since the previous quarter but it is down by 13% year-on-year
BBIO's equity is up by 23% since the previous quarter and by 14% year-on-year
BridgeBio Pharma's revenue has soared by 181% YoY
The stock's price to sales (P/S) is 95% less than its last 4 quarters average of 418.8 and 91% less than its 5-year quarterly average of 243.9

Efficiency

How efficient is BridgeBio Pharma business performance
BBIO's ROS has soared by 97% since the previous quarter and by 53% year-on-year
The ROA has contracted by 41% YoY but it has grown by 24% from the previous quarter
The ROIC has contracted by 35% YoY but it has grown by 21% from the previous quarter

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 55% smaller than its total liabilities
BridgeBio Pharma's quick ratio has soared by 70% from the previous quarter but it has decreased by 2.2% YoY
The current ratio has soared by 67% QoQ but it has decreased by 3.1% YoY
BBIO's debt to equity is down by 29% since the previous quarter and by 17% year-on-year
BBIO's equity is up by 23% since the previous quarter and by 14% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.